SCHEMBL2492855

SCHEMBL2492855

O=C(O)c1ccccc1N1CCCC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.68
PTPN1 P18031 2/20 0.59
ALDH1A1 P00352 5/20 0.56
ALOX15 P16050 1/20 0.56
POLB P06746 2/20 0.54
KDM4E B2RXH2 1/20 0.54
L3MBTL1 Q9Y468 4/20 0.53
GAA P10253 1/20 0.53
MYC P01106 4/20 0.52
NR4A1 P22736 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
ENPP2 Q13822 2/20 0.49
ATM Q13315 2/20 0.49
USP2 O75604 1/20 0.49
GLA P06280 1/20 0.49
TSHR P16473 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
APEX1 P27695 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29467270 1.00 NPC1 (0.68) NPC1PTPN1ALDH1A1ALOX15POLB
SCHEMBL227731 0.98 NPC1 (0.71) NPC1PTPN1ALDH1A1ALOX15POLB
SCHEMBL1715918 0.98 NPC1 (0.71) NPC1PTPN1ALDH1A1ALOX15POLB
SCHEMBL8048603 0.92 ALDH1A1 (0.61) NPC1PTPN1ALDH1A1ALOX15POLB
SCHEMBL28771676 0.91 NPC1 (0.63) NPC1PTPN1ALDH1A1ALOX15POLB
SCHEMBL10607126 0.91 NPC1 (0.62) NPC1PTPN1ALDH1A1ALOX15POLB
SCHEMBL28086833 0.86 NPC1 (0.70) NPC1PTPN1ALDH1A1ALOX15POLB
SCHEMBL3808106 0.85 ALDH1A1 (0.70) NPC1ALDH1A1ALOX15POLBMYC
Hydrochloric Acid SCHEMBL15048754 0.84 NCF1 (0.52) NPC1PTPN1ALDH1A1POLBL3MBTL1
SCHEMBL14528966 0.84 L3MBTL3 (0.59) NPC1PTPN1KDM4EL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211914-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-07-03 US claimed
EP-2378878-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Via Pharmaceuticals, Inc. (US) 2011-10-26 EP claimed
WO-2010077861-A1 INHIBITORS OF DIACYLGLYCEROL ACLYTRANSFERASE VIA PHARMACEUTICALS, INC (US) 2010-07-08 WO claimed
US-20100152445-A1 Inhibitors of Diacylglycerol Acyltransferase MADRIGAL PHARMACEUTICALS, INC. 2010-06-17 US claimed
WO-2025024543-A1 TRICYCLIC UBE2K MODULATORS AND METHODS FOR THEIR USE BPGBIO, INC. (US) 2025-01-30 WO disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 US disclosed
CN-115745874-A Preparation method of o-pyrrolidinyl benzamide compound 南华大学附属第一医院 2023-03-07 CN disclosed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 US disclosed
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 US disclosed
EP-3923991-A1 COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES Ambrx, Inc. (US) 2021-12-22 EP disclosed
WO-2021154966-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2021-08-05 WO disclosed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 US disclosed
EP-2674434-A1 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2013-12-18 EP disclosed
WO-2013091773-A1 TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS MERCK PATENT GMBH (DE) 2013-06-27 WO disclosed
EP-2607364-A1 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators Ares Trading S.A. (CH) 2013-06-26 EP disclosed
EP-1937242-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS NeuroTherapeutics Pharma, Inc. (US) 2008-07-02 EP disclosed
WO-2007047698-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS NEUROTHERAPEUTICS PHARMA, INC. (US) 2007-04-26 WO disclosed
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed
US-4492710-A Substituted pyrrolidinyl-benzoic acid derivatives and a process for their manufacture HOECHST AKTIENGESELLSCHAFT (DE) 1985-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 NPC1 2896/4885PTPN1 3302/4885ALDH1A1 761/4885
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 NPC1 2896/4885PTPN1 3302/4885ALDH1A1 761/4885
US-20100152445-A1 Inhibitors of Diacylglycerol Acyltransferase DGAT2, DGAT1, ACAT2 NPC1 1345/4885PTPN1 3694/4885ALDH1A1 1249/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 NPC1 2896/4885PTPN1 3302/4885ALDH1A1 761/4885
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR NPC1 34/4885PTPN1 317/4885ALDH1A1 2174/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 NPC1 2896/4885PTPN1 3302/4885ALDH1A1 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.